CYChuanzhong Yang

Chuanzhong Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chuanzhong Yang has a total of 293 co-authors. Here are the top co-authors by number of shared publications:

  • Bingchun Lin

    17 shared publications
  • Xueyu Chen

    Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, Women and Children’s Medical Center, Shenzhen School of Clinical Medicine, Southern, Medical University, Shenzhen, China

    16 shared publications
  • Haifeng Zong

    Neonatal Intensive Care Unit, Shenzhen Maternity and Child Healthcare Hospital, Women and Children’s Medical Center, Southern Medical University, Shenzhen 518028, China

    10 shared publications
  • Xueyu Chen

    Laboratory of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, Women and Children’s Medical Center, Southern Medical University, Shenzhen, China

    10 shared publications
  • Zhifeng Huang

    Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital the First School of Clinical Medicine, Southern Medical University Shenzhen China

    10 shared publications
  • Dongshan Han

    Shenzhen Maternity and Child Healthcare Hospital, Women and Children's Medical Center Southern Medical University Shen Zhen Guangdong China

    9 shared publications

Latest Publications

  • Open Access

    Human Milk and Bronchopulmonary Dysplasia in Preterm Infants: The Mediation of Inflammatory Cytokines

    by Yunbei Rao, Xuan Wang, Qingling Li, Lingling Yang, Xiaoyun Xiong, Dongshan Han, Chuanzhong Yang, Xueyu Chen

    Objective: This study investigates the mediating role of inflammatory cytokines in the protective effect of human milk against bronchopulmonary dysplasia (BPD) in preterm infants. Methods: This prospective cohort study included 73 infants born at < 28 weeks' gestation.Infants were classified into high‐dose human milk and high‐dose formula groups according to feeding patterns at 36 weeks postmenstrual age (PMA). Cross‐sectional group comparisons of inflammatory factors at postnatal day 7, day 28, and PMA 36 weeks were examined by Mann–Whitney U test, while longitudinal changes in plasma inflammatory cytokines were evaluated using generalized estimating equations (GEE), and mediation analysis was performed using PROCESS version 4 to assess the potential indirect effects of inflammatory cytokines on the association between human milk exposure and BPD severity. Results: Infants in the high‐dose human milk group had a significantly lower incidence of grade II/III BPD and lower plasma concentrations of CXCL10, IL‐1Ra, and IL‐13 at 36 weeks PMA than those in the high‐dose formula group. Longitudinal GEE analysis showed significant temporal changes in these cytokines but no significant group × time interactions. Mediation analysis demonstrated a significant joint indirect effect through IL‐1Ra and CXCL10 (effect = −0.245, 95% CI −0.487 to −0.046), accounting for 34.9% of the total association between human milk exposure and BPD severity. Conclusion: High human milk feeding was associated with lower BPD severity and a less activated inflammatory profile at 36 weeks PMA. IL‐1Ra‐ and CXCL10‐related inflammatory pathways may partially account for this association, although the observational design precludes definitive causal inference.

  • Open Access

    Pulmonary Surfactant Treatment for Preterm Infants With Respiratory Distress Syndrome: A Nationwide Survey

    by Haifeng Zong, Chuanzhong Yang, Long Chen, Yong Ji, Rong Ju, Jiangqin Liu, Ling Liu, Jingyun Shi, Hui Wu, Lili Wang, et al.

    Background: Pulmonary surfactant is essential for neonatal respiratory distress syndrome (RDS) management, yet national data on how surfactant is used in China are limited. We surveyed current practices and variation in surfactant availability and administration. Methods: In October–December 2022, a nationwide cross‐sectional online survey was completed by one neonatologist from each of 394 hospitals across 30 provinces. Items covered surfactant availability (including delivery room access), product selection, dosing, timing, and administration techniques. Results: Surfactant was available in 96.7% of hospitals; poractant alfa and calsurf were available in 88.6% and 58.1%, respectively. Only 51.6% of hospitals reported surfactant availability in delivery rooms. For the first dose, 200 mg/kg was preferred for poractant alfa (68.8%) and 100 mg/kg for calsurf (63.8%). The reported median time to first dose was 2.0 h after birth; poractant alfa was administered sooner than calsurf (10 vs. 30 min estimated administration time; p < 0.001). Most respondents (79.7%) reported giving surfactant after noninvasive ventilation failure in infants who subsequently required mechanical ventilation, with higher use in tertiary vs. secondary hospitals (82.1% vs. 71.7%; p = 0.03). Intubation‐surfactant‐extubation (INSURE) and less invasive surfactant administration (LISA)/minimally invasive surfactant therapy (MIST) were available in 86.5% and 49.7% of hospitals, respectively. Additionally, 25.1% of the respondents reported combining a surfactant with glucocorticoids for treating RDS. Conclusion: Surfactant use in China shows substantial between‐hospital variation, particularly in delivery room access and less invasive administration. Standardized training and improved resource allocation may reduce disparities and support timely, evidence‐based surfactant therapy.

  • Open Access

    The Diagnostic Value of Lung Ultrasound in Bronchopulmonary Dysplasia Among Preterm Infants with Gestational Age ≤ 28 Weeks

    by Haifeng Zong, Bingchun Lin, Xueyu Chen, Yichu Huang, Jingyu Song, Hongyan Sun, Qingling Li, Sue Zhang, Chuanzhong Yang

    Objective: The aim of this study was to explore the diagnostic value of lung ultrasound (LUS) for bronchopulmonary dysplasia (BPD) in extremely premature infants. Methods: This was a prospective observational cohort study in which infants with gestational age (GA) ≤ 28+6 weeks were included. LUS was performed at least once a week until 36 weeks of postmenstrual age. The LUS characteristics of infants with moderate–severe BPD were compared with those of infants with non–mild BPD. Results: A total of 114 infants were included, of which 69 (60.5%) had non–mild BPD, and 45 (39.5%) had moderate–severe BPD. The mean GA and birth weight of infants with non–mild BPD and moderate–severe BPD were 27.0 ± 1.4 and 26.3 ± 1.6 weeks and 969 ± 184 and 802 ± 228 g, respectively. The proportions of rough pleural lines, fused B-lines, patch-like anechoic appearance on the pleural surface, subpleural speckled hyperechoic appearance, lung consolidation (≥0.5 cm), fuzzy or invisible A-lines, and pleural insect erosion (PIE)-like changes in the moderate–severe BPD group were significantly greater than those in the non–mild BPD group (100% vs. 37.7%, 88.9% vs. 13.0%, 84.4% vs. 7.2%, 73.3% vs. 8.7%, 80.0% vs. 11.6%, 86.7% vs. 10.1%, and 75.6% vs. 5.8%, respectively; p < 0.001). In evaluating moderate–severe BPD, rough pleura had 100.0% (95% CI: 0.921–1.000) in sensitivity, 63.4% (95% CI: 0.518–0.736) in PPV, and 62.3% (95% CI: 0.505–0.728) in specificity. PIE-like changes had 75.6% (95% CI: 0.613–0.858) in sensitivity, 89.5% (95% CI: 0.759–0.958) in PPV, and 94.2% (95% CI: 0.860–0.977) in specificity. Pleura surface irregular patch-like anechoic had 84.4% (95% CI: 0.712–0.923) in sensitivity, 88.4% (95% CI: 0.755–0.949) in PPV, and 92.8% (95% CI: 0.841–0.969) in specificity. Subpleural speckled hyperechogenicity had 73.3% (95% CI: 0.592–0.840) in sensitivity, 84.6% (95% CI: 0.704–0.930) in PPV, and 91.3% (95% CI: 0.824–0.960) in specificity. Conclusions: LUS is a valuable tool for evaluating and diagnosing BPD.

  • Open Access

    Oxytocin ameliorates early life stress-induced anxiety-like behavior by normalizing corticotropin-releasing hormone neuron activity in the PVN

    by Cuihui Li, Yunlong Xu, Bingchun Lin, Xiaoyan Huang, Zhixi Huang, Fuxiang Zheng, Lin Zhu, Yingjie Zhu, Chuanzhong Yang


  • β-hydroxybutyrate alleviates motor impairment and neurological damage in hypoxic-ischemic encephalopathy mice

    by Zhixi Huang, Bingchun Lin, Cuihui Li, Xiaoyan Huang, Lin Zhu, Yunlong Xu, Chuanzhong Yang


  • Open Access

    Inhibition of mitochondrial integrated stress response ameliorates ibuprofen-induced endothelial dysfunction in neonatal hyperoxia-induced lung injury

    by Xuan Wang, Bingchun Lin, Lingling Yang, Xiaoyan Huang, Zhanfeng Li, Haimei Yang, Junyan Zhong, Chuanzhong Yang, Xueyu Chen


  • Open Access

    Lung ultrasound features during the evolution of BPD: a study from an animal model

    by Haifeng Zong, Cuihui Li, Nan Ye, Jingyu Song, Lingling Yang, Su Fang, Jipeng Shi, Xueyu Chen, Chuanzhong Yang

    To explore lung ultrasound (LUS) in the evolution of bronchopulmonary dysplasia (BPD) and the diagnostic value of LUS in BPD. Newborn rats were randomly assigned to the room air (RA) group or the oxygen (O2) group. LUS were performed at 12 h and on the 3rd, 7th, and 10th days to explore the LUS in BPD rats. Hematoxylin-eosin staining and immunohistochemical were analyzed to evaluate pathological characteristics. LUS score (LUSs) in the O2 group was significantly increased on the 7th and 10th days. In the early stage, LUS revealed multiple B-lines and air bronchograms. In the late stage, LUS revealed anechoic echoic areas on the pleural surface and scattered dot-like hyperechoic patterns in the lung field. The LUS findings were consistent with the pathological results. There was a strong positive correlation between LUS and pathological findings. LUS can be used to monitor the evolution of BPD.


  • Umbilical cord blood platelet lysate preserves myofibroblast migration and mitigates hyperoxic lung injury

    by Xueyu Chen, Bingchun Lin, Zilu Huang, Xuan Wang, Dongshan Han, Lingling Yang, Zhifeng Huang, Chuanzhong Yang

    Background Traditionally, platelets were thought to originate solely in the bone marrow, but emerging evidence now indicates that the lung is a major site of platelet generation. Our previous work, along with studies by others, has revealed decreased platelet counts and enhanced platelet activation in BPD patients, linking platelets to the disease’s pathogenesis. Methods We investigated the protective effects and underlying mechanisms of umbilical cord blood (UCB) platelets in mitigating hyperoxia-induced lung injury in neonatal rats and in vitro. Results Compared with platelet-poor plasma (PPP), UCB-derived platelets (PLT) treatment preserved lung development, as evidenced by an increased density of secondary crests and reduced small arterial wall thickness. Given that secondary crest formation depends on myofibroblast activity, we further examined the cellular function of myofibroblasts isolated from the lungs of control and hyperoxic mice. We found that hyperoxia impaired myofibroblast function, particularly their migration capacity, which can be prevented by UCB platelet lysate. Conclusion These findings suggest that UCB PLT preserve lung development by protecting myofibroblast migratory capacity, offering new insights into BPD pathogenesis and potential therapeutic strategies. Impact Hyperoxia impairs myofibroblast function, particularly their migratory capacity, which can be prevented by umbilical cord blood platelet lysate. Umbilical cord blood platelets preserve lung development in hyperoxia-exposed newborn rats by increasing the density of secondary crests and mitigating vascular remodeling in small arteries. These findings underscore the promising therapeutic potential of umbilical cord blood-derived platelets for the management of BPD.

  • Open Access

    A Preterm Infant With Gestational Age of 21 +4 Weeks

    by Haifeng Zong, Bingchun Lin, Yingsui Huang, Shan Jiang, Yurong Yuan, Xiaoyuan Xiong, Zhichun Feng, Chuanzhong Yang

    We report a case of a male infant who was conceived through in vitro fertilization, with a gestational age of 21 +4 weeks. The infant was discharged home at 42 weeks' postmenstrual age without significant cranial morbidities.

  • Open Access

    Continuous renal replacement therapy in a neonate with methylmalonic acidemia and severe hyperammonemia: A case report

    by Bingchun Lin, Yichu Huang, Yanliang Yu, Xiaoyun Xiong, Chuanzhong Yang

    Background: Methylmalonic acidemia (MMA) is a rare disease that is often misdiagnosed and overlooked. Metabolic acidosis and severe hyperammonemia are severe morbidities of MMA that demand immediate treatment. Case-diagnosis: Here, we describe an MMA neonate with severe hyperammonemia and acidosis that was successfully rescued by continuous renal replacement therapy. A 6-day-old male neonate, with a gestational age of 39 + 3 weeks and a birth weight of 2880 g, was admitted to the emergency with the symptoms of “cyanosis of the face and coma for 2 hours.” The infant was suffering from hypoglycemia, hypocalcemia, severe hyperammonemia, and severe metabolic acidosis. After admission, the blood ammonia continued to rise, and continuous renal replacement therapy was promptly administered until the patient gradually regained consciousness. Blood tandem mass spectrometry and profiles revealed that methylmalonic acid and methyl citrate levels were significantly enhanced. Two heterozygous mutations were detected in the MUT gene, confirming the diagnosis of methylmalonic acidemia mut. Conclusions: The patient’s symptoms gradually improved after receiving vitamin B12, l-carnitine, and specialized milk feeding. The patient was successfully discharged from the hospital after 41 days.